EUVIMEDEUVIMED entdecken
Crossref

Dual‐Targeted Engineered Bacterial Outer Membrane Vesicles for Hepatocellular Carcinoma Immunotherapy

Yongchao Li, Tianchuan Zhu, Jian Chen, Kecheng Liu, Chunren Wei, Qiongyan Fang, Xi Huang, Hong Shan

Advanced Functional Materials · 2024-10 · 34 (41)

DOI: 10.1002/adfm.202401355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 16.07.2024. Verfasst von Yongchao Li und 7 weiteren Autor:innen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cluster of differentiation 47 (CD47) is an important innate immune checkpoint that empowers tumors to send “don't eat me” signals, leading to immune escape. CD47 monoclonal antibodies have achieved remarkable therapeutic success in hematological malignancies. However, their efficacy in solid tumors is limited, mainly because of immunosuppression in the tumor microenvironment. In addition, hematotoxicity severely hinders the clinical translation of CD47 antibodies. Here, a novel genetically programmed nanovesicle, OMV‐CD47/GPC3, is generated for hepatocellular carcinoma (HCC) immunotherapy by fusing anti‐CD47 nanobodies and anti‐GPC3 scFv onto bacterial outer membrane vesicles (OMVs). Following intravenous administration, dual‐targeted OMV‐CD47/GPC3 specifically recognized tumor cells expressing both CD47 and GPC3, thereby actively targeting and accumulating at the orthotopic HCC tumor site without hematotoxicity. OMV‐CD47/GPC3 potently blocked tumor CD47 and promoted macrophage phagocytosis. More importantly, immunogenic OMV‐CD47/GPC3 can effectively remodel the tumor immune microenvironment of orthotopic HCC, especially reprogram tumor‐associated macrophages (TAMs) to the M1‐phenotype and promote dendritic cell maturation, synergistically inducing a robust CD8 + T cell‐mediated anti‐tumor immune response. With the two‐pronged approach of immune checkpoint inhibition and immune activation, engineered OMV‐CD47/GPC3 significantly suppressed orthotopic HCC growth and prevented tumor recurrence and metastasis, thus providing a promising strategy for HCC immunotherapy.

Zitieren

APA

Li, Y., Zhu, T., Chen, J., Liu, K., Wei, C., Fang, Q., Huang, X., & Shan, H. (2024). Dual‐Targeted Engineered Bacterial Outer Membrane Vesicles for Hepatocellular Carcinoma Immunotherapy. Advanced Functional Materials, 34(41). https://doi.org/10.1002/adfm.202401355

Vancouver

Li Y, Zhu T, Chen J, Liu K, Wei C, Fang Q, et al. Dual‐Targeted Engineered Bacterial Outer Membrane Vesicles for Hepatocellular Carcinoma Immunotherapy. Advanced Functional Materials. 2024;34(41). doi:10.1002/adfm.202401355

BibTeX
@article{Li2024,
  author = {Li, Yongchao and Zhu, Tianchuan and Chen, Jian and Liu, Kecheng and Wei, Chunren and Fang, Qiongyan and Huang, Xi and Shan, Hong},
  title = {Dual‐Targeted Engineered Bacterial Outer Membrane Vesicles for Hepatocellular Carcinoma Immunotherapy},
  journal = {Advanced Functional Materials},
  year = {2024},
  volume = {34},
  number = {41},
  doi = {10.1002/adfm.202401355}
}
Kostenlos starten →